Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 4/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | AXL | P30530 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517434 | 0.78 | IDO1 (0.40) | TRPA1IDO1METAP2ROCK2ROCK1 | |
| SCHEMBL9939628 | 0.78 | IDO1 (0.40) | TRPA1IDO1METAP2ROCK2ROCK1 | |
| SCHEMBL22281317 | 0.76 | TRPA1 (0.42) | TRPA1IDO1METAP2NOS1AXL | |
| SCHEMBL16746127 | 0.76 | TRPA1 (0.42) | TRPA1IDO1METAP2ROCK2NOS1 | |
| SCHEMBL20618762 | 0.75 | TRPA1 (0.44) | TRPA1IDO1METAP2NOS1AXL | |
| SCHEMBL62144 | 0.75 | NOS1 (0.46) | TRPA1IDO1METAP2NOS1AXL | |
| SCHEMBL14803988 | 0.75 | NOS1 (0.46) | TRPA1IDO1METAP2ROCK1NOS1 | |
| SCHEMBL27192232 | 0.75 | NOS1 (0.42) | TRPA1IDO1METAP2ROCK2ROCK1 | |
| SCHEMBL29957643 | 0.74 | TRPA1 (0.38) | TRPA1IDO1ROCK2ROCK1NOS1 | |
| SCHEMBL10282903 | 0.74 | TRPA1 (0.38) | TRPA1IDO1METAP2NOS1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2788332-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN, INC. (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013086229-A1 | BICYCLIC ARYL AND HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| EP-1745024-B1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NOVARTIS INT PHARM LTD (BM) | 2012-04-25 | — | — | EP | disclosed |
| EP-1745024-B1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NOVARTIS INT PHARM LTD (BM) | 2012-04-25 | — | — | EP | disclosed |
| EP-1565452-B1 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NOVARTIS INT PHARM LTD (BM) | 2012-04-04 | — | — | EP | disclosed |
| EP-1745024-A1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745039-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | Neurogen Corporation (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745033-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006004589-A2 | 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES | NEUROGEN CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110991-A1 | 1-ARYL-4-SUBSTITUTED ISOQUINOLINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110416-A2 | 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES | NEUROGEN CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-1565452-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINES AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| WO-2004043925-A2 | 3-SUBSTITUTED-6-ARYL PYRIDINED AS LIGANDS OF C5A RECEPTORS | NEUROGEN CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277654-A1 | 4,5-Disubstituted-2-aryl pyrimidines | C5AR2, C3AR1, C5AR1 | TRPA1 249/4885IDO1 349/4885METAP2 1641/4885 |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | TRPA1 61/4885IDO1 2052/4885METAP2 4517/4885 |
| US-20040158067-A1 | 3-substituted-6-aryl pyridines | C3AR1, C5AR1, C5AR2 | TRPA1 339/4885IDO1 253/4885METAP2 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.